Latest news: EXACT Therapeutics

Sep. 03	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Jun. 30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
Jun. 26	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE
Jun. 26	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer	CI
Jun. 17	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application	MT
May. 29	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo	MT
Apr. 09	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer	CI
Jan. 27	Exact Therapeutics as Announces Positive Initial Safety Read-Out from the Phase 2 Enact Trial in Pancreatic Cancer	CI
Nov. 24	Exact Therapeutics introduces new long-term incentive program	RE
25-09-25	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-25	Exact Therapeutics H1 operating loss widens to NOK 45.9 million	RE
25-08-12	EXACT Therapeutics AS to Present at the European Society for Medical Oncology Congress 2025	CI

More news

Press Releases: EXACT Therapeutics

Sep. 04	EXACT Therapeutics publishes shareholder information regarding the delisting	AQ
Sep. 03	EXACT Therapeutics first half 2026 interim report	AQ
Aug. 31	EXACT Therapeutics AS - Issuance of share options	AQ
Jul. 02	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
Jun. 30	EXACT Therapeutics AS - Removal from trading	AQ

More press releases

Managers and Directors: EXACT Therapeutics

Manager	Title	Age	Since
Per Walday CEO	Chief Executive Officer	66	2022-06-05
Svein Kvåle COO	Chief Operating Officer	-	2011-12-31
John Edminson DFI	Director of Finance/CFO	-	2022-09-30

Director	Title	Age	Since
Masha Paule Nathalie Strømme CHM	Chairman	55	2018-06-21
Anders Wold CHM	Chairman	-	2022-06-07
Ann-Tove Kongsnes BRD	Director/Board Member	59	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT THERAPEUTICS	0.00%	+0.63%	-61.90%	-94.67%	5.34M
LONZA GROUP AG	+1.46%	+5.87%	+5.75%	+33.71%	47.56B
IQVIA HOLDINGS INC.	+2.67%	+2.31%	+47.50%	+38.37%	44.09B
BEONE MEDICINES AG	-1.38%	+3.42%	+9.39%	+88.88%	41.5B
REVOLUTION MEDICINES, INC.	+4.78%	+2.01%	+352.12%	+566.20%	40.88B
CELLTRION, INC.	-0.62%	+0.11%	+1.12%	+46.02%	29.67B
MEDPACE HOLDINGS, INC.	+0.56%	+0.67%	+25.08%	+155.71%	17.23B
EUROFINS SCIENTIFIC SE	+2.05%	+4.04%	+24.47%	+41.67%	15.06B
ASCENDIS PHARMA A/S	+3.39%	-6.86%	-	-	14.65B
TEMPUS AI, INC.	+7.38%	+17.54%	-2.25%	-	13.82B
Average	+2.03%	+0.68%	+44.59%	+109.49%	26.45B
Weighted average by Cap.	+1.89%	+0.96%	+71.88%	+147.49%

See all sector performances

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-24	NOK 0.8000	0.00%	0
26-09-23	NOK 0.8000	+1.27%	54,818
26-09-22	NOK 0.7900	0.00%	0
26-09-21	NOK 0.7900	+0.64%	56,100
26-09-18	NOK 0.7850	0.00%	0

Real-time Oslo Bors

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Oslo Bors 10:45:00 2026-09-24 am EDT			5-day change	1st Jan Change
0.8000 ^NOK	0.00%		+0.63%	-42.03%

Market Cap	50.61M 5.32M 4.68M 4.41M 4.02M 7.52M 510M 7.58M 52.91M 20.5M 260M 19.96M 19.53M 845M	P/E 2024	-2.49x	P/E 2025	-1x
Enterprise Value	26.7M 2.8M 2.47M 2.33M 2.12M 3.97M 269M 4M 27.91M 10.82M 137M 10.53M 10.3M 446M	EV / Sales 2024	-	EV / Sales 2025	1,074,437,000x
Free-Float	60.85%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Oslo Bors	EXTX	Real-time
Deutsche Boerse AG	56F	Delayed

1 week	+0.63%
Current month	+3.90%
1 month	+6.67%
3 months	+11.89%
6 months	-70.37%
Current year	-42.03%

1 week	0.77	0.8
1 month	0.6	0.85
Current year	0.58	2.7
1 year	0.58	2.78
3 years	0.58	17
5 years	0.58	21
10 years	0.58	53.59

EXACT Therapeutics Stock

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Valuation: EXACT Therapeutics

Chart: EXACT Therapeutics

Latest news: EXACT Therapeutics

Press Releases: EXACT Therapeutics

Quotes and Performance

Price Extremes

Managers and Directors: EXACT Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/23	Anders Wold	Buy	Chairman	2,500	0.0083%
1/4/23	Svein Kvåle	Buy	Founder	2,500	0.0083%
1/4/23	John Edminson	Buy	Chief Financial Officer	2,500	0.0083%

	2024	2025
Net sales	-	0.06 0.01 0.01 0.01 0 0.01 0.59 0.01 0.06 0.02 0.3 0.02 0.02 0.99
Net income	-52.33M -5.5M -4.84M -4.56M -4.16M -7.78M -528M -7.84M -54.7M -21.2M -269M -20.64M -20.19M -874M	-86.97M -9.14M -8.04M -7.58M -6.91M -12.93M -877M -13.03M -90.91M -35.23M -446M -34.3M -33.56M -1.45B
Net Debt	-98.89M -10.39M -9.14M -8.61M -7.86M -14.7M -997M -14.81M -103M -40.06M -508M -39.01M -38.16M -1.65B	-23.91M -2.51M -2.21M -2.08M -1.9M -3.55M -241M -3.58M -25M -9.69M -123M -9.43M -9.23M -399M